Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
Church & Dwight Co
CHD
$23.2B
| $133M | 0.12% |
1,726,352
-509,948
| -23% | -$37.1M |
2019 Q1
5 quarters
|
|
177
Hormel Foods
HRL
$10.7B
| $133M | 0.11% |
2,755,613
+1,623,154
| +143% | +$77.6M |
2019 Q4
2 quarters
|
|
178
Ubiquiti
UI
$39.3B
| $132M | 0.11% |
757,382
+16,200
| +2% | +$2.72M |
2016 Q1
17 quarters
|
|
|
SNP
179
DELISTED
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
| $131M | 0.11% |
3,130,604
+332,900
| +12% | +$15.7M |
2015 Q1
21 quarters
|
|
|
SWCH
180
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $130M | 0.11% |
7,291,063
-156,002
| -2% | -$2.73M |
2018 Q4
6 quarters
|
|
181
Usana Health Sciences
USNA
$268M
| $130M | 0.11% |
1,768,666
+186,966
| +12% | +$14.7M |
2013 Q2
28 quarters
|
|
182
Check Point Software Technologies
CHKP
$13.7B
| $129M | 0.11% |
1,202,509
+770,501
| +178% | +$81.6M |
2017 Q1
13 quarters
|
|
183
Tenaris
TS
$28.6B
| $129M | 0.11% |
9,975,848
+1,217,400
| +14% | +$16.1M |
2018 Q4
6 quarters
|
|
184
Crocs
CROX
$5.59B
| $128M | 0.11% |
3,475,311
-1,334,800
| -28% | -$35.3M |
2015 Q3
19 quarters
|
|
185
ZTO Express
ZTO
$14.8B
| $128M | 0.11% |
3,474,400
+1,920,700
| +124% | +$61.2M |
2019 Q3
3 quarters
|
|
186
Lumentum
LITE
$95.6B
| $128M | 0.11% |
1,566,242
-650,900
| -29% | -$49.6M |
2019 Q4
2 quarters
|
|
187
Medifast
MED
$128M
| $127M | 0.11% |
915,910
+22,000
| +2% | +$2.02M |
2013 Q2
28 quarters
|
|
188
Wells Fargo
WFC
$247B
| $126M | 0.11% |
4,916,926
+1,833,315
| +59% | +$50.2M |
2018 Q3
7 quarters
|
|
189
Sturm, Ruger & Co
RGR
$702M
| $126M | 0.11% |
1,653,276
+221,500
| +15% | +$13.5M |
2015 Q3
19 quarters
|
|
190
W.W. Grainger
GWW
$60.2B
| $125M | 0.11% |
398,900
+75,300
| +23% | +$21.8M |
2019 Q1
5 quarters
|
|
191
Dr. Reddy's Laboratories
RDY
$10.2B
| $125M | 0.11% |
11,759,690
+1,784,450
| +18% | +$18.2M |
2018 Q1
9 quarters
|
|
192
Alamos Gold
AGI
$13.5B
| $124M | 0.11% |
13,231,956
+30,485
| +0.2% | +$234K |
2017 Q4
10 quarters
|
|
193
Ambev
ABEV
$49B
| $123M | 0.11% |
46,525,386
-1,432,490
| -3% | -$3.38M |
2017 Q4
10 quarters
|
|
194
Enbridge
ENB
$104B
| $123M | 0.11% |
4,031,781
-1,221,900
| -23% | -$37.5M |
2018 Q3
7 quarters
|
|
|
CEO
195
DELISTED
CNOOC Limited
CEO
| $123M | 0.11% |
1,086,474
+53,000
| +5% | +$5.98M |
2015 Q2
20 quarters
|
|
196
Dolby
DLB
$5.51B
| $122M | 0.11% |
1,848,357
-176,400
| -9% | -$10.6M |
2013 Q2
28 quarters
|
|
|
VMW
197
DELISTED
VMware, Inc
VMW
| $122M | 0.11% |
785,767
+14,627
| +2% | +$2.01M |
2014 Q3
23 quarters
|
|
|
CZZ
198
DELISTED
Cosan Limited
CZZ
| $122M | 0.11% |
8,074,794
-903,648
| -10% | -$11.8M |
2013 Q2
28 quarters
|
|
199
AXIS Capital
AXS
$7.1B
| $121M | 0.1% |
2,980,213
+287,984
| +11% | +$11.1M |
2014 Q2
24 quarters
|
|
200
AngloGold Ashanti
AU
$45.8B
| $120M | 0.1% |
4,081,635
+578,950
| +17% | +$14.3M |
2017 Q3
11 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.